Erythromycin Ethylsuccinate

Summary

Erythromycin Ethylsuccinate (CHEMBL1200688) is an approved small molecule; indicated across 5 conditions including pertussis and type 1 diabetes mellitus.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Indications: 5 conditions
• Chemistry: 862.1 Da · C43H75NO16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200688
Name	Erythromycin Ethylsuccinate
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	443953
ChEBI	CHEBI:31555
Molecular formula	C43H75NO16
Molecular weight	862.1
InChIKey	NSYZCCDSJNWWJL-YXOIYICCSA-N

SMILES: CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)OC(=O)CCC(=O)OCC)(C)O)C)C)O)(C)O

IUPAC name: 4-O-[(2S,3R,4S,6R)-4-(dimethylamino)-2-[[(3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] 1-O-ethyl butanedioate

ChEBI definition: A erythromycin derivative that is erythromycin A in which the hydroxy group at position 3R is substituted by a (4-ethoxy-4-oxobutanoyl)oxy group. It is used for the treatment of a wide variety of bacterial infections.

Also known as: Anamycin, Arpimycin, E-mycin e, E.e.s., E.e.s. 200, E.e.s. 400, Eritrocina, Eryliquid, Erymin, Eryped, Erythroden, Erythromycin ethylsuccinate

Patent coverage: 26,761 distinct patent families (51,700 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Solute carrier organic anion transporter family member 1B1, Solute carrier organic anion transporter family member 1B3, Beta-lactamase.

Bioactivity

ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P00811	7.2	Potency	63.1	nM	CHEMBL_ACT_4673549
SLCO1B3	5.79	Ki	1610	nM	CHEMBL_ACT_13798700
SLCO1B1	5.78	Ki	1670	nM	CHEMBL_ACT_13800699
SLCO1B3	5.68	IC50	2089	nM	CHEMBL_ACT_13798636
SLCO1B1	5.52	IC50	3020	nM	CHEMBL_ACT_13800635

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
pertussis	4	MONDO:0005077	EFO:0000650

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
type 1 diabetes mellitus	1	MONDO:0005147	MONDO:0005147
amyotrophic lateral sclerosis	1	MONDO:0004976	MONDO:0004976

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).